ArticleJournal of global health2025
Exploring the complex relationship between systemic lupus erythematosus and coronavirus disease 2019: genetic insights and potential protective mechanisms.
Article in Journal of global health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Severe coronavirus disease 2019 (COVID-19) and systemic lupus erythematosus (SLE) have been reported to share common gene loci, but the causal relationship between them remains controversial. Methods: We conducted a linkage disequilibrium score regression analysis to assess the genetic correlations between SLE and the two traits (infection and severity) of COVID-19 in European populations. Mendelian randomisation analysis was then performed to explore the causal effect of SLE on susceptibility to these traits in both European and East Asian data sets. Lastly, enrichment analysis and Protein-Protein Interactions analysis were used to identify key pathways and genes involved, providing insights into the possible mechanism underlying the complex relationship between SLE and COVID-19. Results: A significant genetic correlation was observed between SLE and COVID-19 severity (genetic correlation (rg) = 0.340, P = 0.001). However, no significant genetic correlation was found with COVID-19 infection. Mendelian randomisation analysis revealed a negative causal effect of SLE on both COVID-19 infection (odds ratio (OR) = 0.986; 95% confidence interval (CI) = 0.975-0.997, P = 0.009) and severity (OR = 0.955; 95% CI = 0.921-0.990, P = 0.012) in European populations, with similar findings replicated in East Asians. Notably, interleukin-6 (IL-6) and tumour necrosis factor were identified as hub cytokines connecting SLE to COVID-19 infection, while IL-6 and interleukin-10 (IL-10) were pivotal in connecting SLE to COVID-19 severity. Conclusions: This study reveals a potentially protective effect of SLE against COVID-19 infection and severity, with IL-6, tumour necrosis factor, and IL-10 playing key roles. Despite immunosuppressant use, SLE patients showed no increased risk of severe outcomes, likely due to their heightened caution in avoiding infection. These findings challenge common assumptions and highlight the need for further research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.